Despite two years of ongoing national emergency, including a direct confrontation with Iran, Israeli high-tech demonstrates remarkable resilience, with strong investment figures, a rise in deal volume, and renewed IPO activity. Adv. Tal Freilich's article focuses on the strength of Israel’s tech ecosystem, with a look at prominent sectors such as cyber and AI, and the return of mega-deals.
Tal Freilich Hay
Electra City Tower
58 Harekevet St.
Tel Aviv
6777016
Tal Freilich Hay
Tal is an associate in our firm's Corporate Department.
Adv. Tal Freilich provides ongoing legal advice to technology companies, venture capital funds, and private funds, as well as to entrepreneurs and startups. Her advice spans various fields, such as raising capital and funding, mergers and acquisitions, and asset acquisition.
In addition, Tal offers legal counsel to companies in the course of their ongoing activity, including on issues of distribution, manufacturing, franchising, licensing, and intellectual property.
Before joining Barnea, Tal worked for a leading Israeli law firm.
Education:
Interdisciplinary Center Herzliya, LL.B. and B.A. in Psychology, 2016
Admission:
Israel Bar Association, 2017
Insights & News - Tal Freilich Hay:
March 25, 2026
Mechanisms for Determining the Final Purchase Price in M&A Transactions: Lockbox or Working Capital Adjustment?
One of the key decisions when structuring a M&A transaction is the optimal mechanism for determining the final purchase price. It is one of the primary tools for balancing risk between the parties and ensuring the transaction’s success. The two most common and widely accepted methods in M&A transactions are the lockbox mechanism and the working capital adjustment mechanism.
December 22, 2025
Barnea: Representing Syremis in a USD 165 Million Investment Round
Adv. Michael Barnea, Adv. Misha Gitterman, and Adv. Tal Freilich represented Syremis Therapeutics, a spin-off of Clexio Biosciences, in the completion of a USD 165 million Series A financing round co-led by Dexcel Pharma and Third Rock Ventures, with participation from Bain Capital Life Sciences, Google Ventures, and QVT.
July 24, 2025